|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a
The purpose of this study is to evaluate:
The side effects of BAY1129980 when given every 21 days different dose levels.
Determine the dose level of BAY1129980 that should be tested in future clinical research studies.
Measure how much BAY1129980 is in the blood at specific times after administration.
If treatment with BAY1129980 shows any effect on reducing the tumor growth.
If there are specific biomarkers that might be able to explain why some patients respond to treatment and others do not.
If treatment with BAY1129980 causes an immune response from the body against the drug (immunogenicity).
100 项与 LYPD3 x Tubulin 相关的临床结果
100 项与 LYPD3 x Tubulin 相关的转化医学
0 项与 LYPD3 x Tubulin 相关的专利(医药)